Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS Paralympic athlete Louzanne ready for Rio
2016-09-12

Description: Louzanne ready for Rio Tags: Louzanne ready for Rio

Rufus Botha (coach, left), Louzanne Coetzee,
and her guide Khothatso Mokone during a training
session for the Rio 2016 Paralympic Games.
Photo: Johan Roux

“Coetzee is someone with a lot of perseverance. She is becoming a world-class athlete with the help of her guide, Khothatso Mokone.” These were the words from Rufus Botha, the coach of 23-year-old Louzanne Coetzee.

Coetzee, who works at the Institute for Reconciliation and Social Justice at the University of the Free State (UFS), said that the 2016 Paralympics in Rio de Janeiro was never a big dream for her, because she never thought she was good enough to make it, but God had a different plan for her life.

Louzanne and her formidable team

Coetzee said that she still struggles to come to terms with the fact that she is competing at the Paralympics and experiences a rollercoaster of emotions. “I am excited, nervous, and confused all at the same time.”

According to Botha, who has been her coach for the past four years, Coetzee and her guide have such a unique rhythm and work together well. “After Mokone, also a former Kovsie, stepped into the picture, everything just escalated.”

The 2016 Paralympics and beyond

“Coetzee is someone with a lot of
perseverance and is becoming a
world-class athlete.”


“Making the Paralympic team is already a bonus. The next target we are aiming for, is for her to reach the finals in the 1500 m,” Botha said.

Coetzee and Mokone were included in the South African team to participate in Rio from 7 to 18 September 2016. Her heat takes place on 15 September 2016 and the finals of the 1500 m on 17 September 2016.

Coetzee’s main goal after the Paralympics is the World ParaAthletics Championships in London 2017.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept